National registry for liver cancer patients
JADE - Clinical Research Platform on Treatment and Outcome in Patients With Hepatocellular or Cholangiocellular Cancer
This study is creating a national registry to track and gather information about patients with liver cancer to help improve treatment and understand their experiences over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | iOMEDICO AG Industry-sponsored |
| Locations | 1 site (Multiple Locations) |
| Trial ID | NCT04510740 on ClinicalTrials.gov |
What this trial studies
This project establishes a national, prospective, longitudinal cohort study in Germany to create a tumor registry platform for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma (CCC). It aims to document uniform data on patient characteristics, treatment approaches, and disease progression over a period of up to three years. The registry will also collect patient-reported outcomes and establish a decentralized biobank to support future research. Data on systemic treatments, surgeries, and health-related quality of life will be evaluated throughout the study.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with confirmed HCC or CCC at any stage of the disease.
Not a fit: Patients receiving only best supportive care without any active treatment will not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of liver cancer treatments and improve patient outcomes through better-informed therapeutic strategies.
How similar studies have performed: Other observational studies have shown success in similar approaches, indicating the potential for valuable insights into treatment patterns and patient outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Confirmed hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCC) als early, intermediate or advanced/metastatic stage * Age ≥ 18 years * Signed and dated informed consent (IC): * For participation in the PRO module: Before primary locoregional therapy or start of first systemic treatment * For no participation in the PRO module: No later than 8 weeks after primary locoregional therapy or start of first systemic treatment Exclusion criteria: Patients treated with best supportive care (BSC) only (i.e. no surgery, no radiotherapy, no ablative procedures, no systemic anti-tumoral therapies)
Where this trial is running
Multiple Locations
- Multiple sites all over germany — Multiple Locations, Germany (Recruiting)
Study contacts
- Study coordinator: iOMEDICO AG
- Email: info@iomedico.com
- Phone: +49 761 15242-0
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.